Checkpoint Therapeutics, Inc. (CKPT): Price and Financial Metrics


Checkpoint Therapeutics, Inc. (CKPT)

Today's Latest Price: $2.81 USD

0.07 (2.55%)

Updated Sep 25 4:00pm

Add CKPT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CKPT Stock Summary

  • For CKPT, its debt to operating expenses ratio is greater than that reported by merely 0.34% of US equities we're observing.
  • CKPT's price/sales ratio is 127.91; that's higher than the P/S ratio of 97.66% of US stocks.
  • As for revenue growth, note that CKPT's revenue has grown -70.29% over the past 12 months; that beats the revenue growth of only 2.17% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Checkpoint Therapeutics Inc are SYRS, LPTX, BBIO, GLYC, and SURF.
  • CKPT's SEC filings can be seen here. And to visit Checkpoint Therapeutics Inc's official web site, go to www.checkpointtx.com.
CKPT Daily Price Range
CKPT 52-Week Price Range

CKPT Stock Price Chart Technical Analysis Charts


CKPT Price/Volume Stats

Current price $2.81 52-week high $4.50
Prev. close $2.74 52-week low $1.05
Day low $2.68 Volume 732,791
Day high $2.85 Avg. volume 598,556
50-day MA $2.52 Dividend yield N/A
200-day MA $1.95 Market Cap 168.71M

Checkpoint Therapeutics, Inc. (CKPT) Company Bio


Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.


CKPT Latest News Stream


Event/Time News Detail
Loading, please wait...

CKPT Latest Social Stream


Loading social stream, please wait...

View Full CKPT Social Stream

Latest CKPT News From Around the Web

Below are the latest news stories about Checkpoint Therapeutics Inc that investors may wish to consider to help them evaluate CKPT as an investment opportunity.

How Much Did Checkpoint Therapeutics'(NASDAQ:CKPT) Shareholders Earn From Share Price Movements Over The Last Three Years?

It is a pleasure to report that the Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) is up 57% in the last quarter. But...

Yahoo | September 19, 2020

INO, CKPT among premarket losers

Checkpoint Therapeutics (CKPT) -14% after bought deal offering.LightInTheBox Holding (LITB) -6%.Inovio Pharmaceuticals (INO) -4%....

Seeking Alpha | September 18, 2020

Checkpoint Therapeutics' cosibelimab shows encouraging action in skin cancer study

Checkpoint Therapeutics (CKPT) perks 6% premarket after announcing updated interim results from the ongoing Phase 1 clinical trial of its anti-PD-L1 antibody, Cosibelimab (formerly referred to as CK-301), in patients with advanced cancers, including the registration-enabling cohort of patients with metastatic cutaneous squamous cell carcinoma (mCSCC).The interim results were presented at the European...

Seeking Alpha | September 17, 2020

Checkpoint Therapeutics To Release Significant Drug Data At This Week's ESMO Congress

With interim results from a pivotal clinical trial of its lead PD-L1 checkpoint inhibitor incoming, biotech firm Checkpoint Therapeutics (NASDAQ: CKPT) is poised to deliver an important update on the drug's efficacy and tolerability in its initial indication as a potential treatment for cutaneous squamous cell carcinoma (CSCC) at this week's European Society for Medical Oncology (ESMO) Virtual Congress.Following up on a prior interview on the status of its leading immunotherapy product candidate, cosibelimab, Benzinga spoke with Checkpoint Therapeutics President and CEO James Oliviero about the progress of the pivotal trial in CSCC and the evolving regulatory landscape in which it's being conducted.According to Oliviero, "The ESMO data is going to include approximately ...

Yahoo | September 14, 2020

Checkpoint Therapeutics to Participate in Three September 2020 Virtual Investor Conferences

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James F. Oliviero, President and Chief Executive Officer, will participate in three virtual investor conferences in September 2020. Details of the events are as follows: * H.C. Wainwright 22nd Annual Global Investment Conference: Presentation on Monday, September 14, 2020, at 3:30 p.m. EDT * Cantor Virtual Global Healthcare Conference: Presentation on Wednesday, September 16, 2020, at 10:00 a.m. EDT * Lake Street Capital Markets 4th Annual Best Ideas Growth (BIG4) Conference: Virtual one-on-one meetings on Thursday, September 17, 2020Webcasts of the presentations will be available on the Events pa...

Yahoo | September 10, 2020

Read More 'CKPT' Stories Here

CKPT Price Returns

1-mo 32.55%
3-mo 40.50%
6-mo 86.09%
1-year 12.40%
3-year -64.79%
5-year N/A
YTD 63.37%
2019 -5.49%
2018 -53.09%
2017 N/A
2016 N/A
2015 N/A

Continue Researching CKPT

Here are a few links from around the web to help you further your research on Checkpoint Therapeutics Inc's stock as an investment opportunity:

Checkpoint Therapeutics Inc (CKPT) Stock Price | Nasdaq
Checkpoint Therapeutics Inc (CKPT) Stock Quote, History and News - Yahoo Finance
Checkpoint Therapeutics Inc (CKPT) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7838 seconds.